Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash & Current Investments: 2016-2024

Historic Cash & Current Investments for Rocket Pharmaceuticals (RCKT) over the last 9 years, with Dec 2024 value amounting to $372.3 million.

  • Rocket Pharmaceuticals' Cash & Current Investments fell 8.91% to $369.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 4.40%. This contributed to the annual value of $372.3 million for FY2024, which is 0.22% down from last year.
  • Rocket Pharmaceuticals' Cash & Current Investments amounted to $372.3 million in FY2024, which was down 0.22% from $373.2 million recorded in FY2023.
  • Rocket Pharmaceuticals' 5-year Cash & Current Investments high stood at $521.6 million for FY2020, and its period low was $356.4 million during FY2022.
  • Moreover, its 3-year median value for Cash & Current Investments was $372.3 million (2024), whereas its average is $367.3 million.
  • As far as peak fluctuations go, Rocket Pharmaceuticals' Cash & Current Investments skyrocketed by 71.50% in 2020, and later fell by 25.47% in 2021.
  • Over the past 5 years, Rocket Pharmaceuticals' Cash & Current Investments (Yearly) stood at $521.6 million in 2020, then decreased by 25.47% to $388.7 million in 2021, then fell by 8.32% to $356.4 million in 2022, then grew by 4.71% to $373.2 million in 2023, then fell by 0.22% to $372.3 million in 2024.